首页> 外文期刊>Transplantation Proceedings >Impact of pretransplant MELD score on posttransplant outcome in living donor liver transplantation.
【24h】

Impact of pretransplant MELD score on posttransplant outcome in living donor liver transplantation.

机译:活体供体肝移植中移植前MELD评分对移植后结局的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

It is not clear whether pretransplantation MELD (model for End-Stage Liver Disease) score can foresee posttransplant outcome. We retrospectively evaluated 80 adult patients (55 men, 25 women) who underwent living donor liver transplantation between September 1998 and March 2003. Five other patients with fulminant hepatitis were excluded. The UNOS-modified MELD scores were calculated to stratify patients into three groups: group 1) MELD score less than 15 (n = 13); group 2) MELD score 15 to 24 (n = 36); and group 3) MELD score 25 and higher (n = 26). The patients were predominantly men (n = 52, 69.3%) with overall mean age of 43.9 years (range, 17-62 years). The mean follow-up was 15.7 months (range, 1-47; median = 14 months). The mean MELD score was 22.7 (range, 9-50; median = 21). The overall 1- and 2-year patient survivals were 87% and 78.7%, respectively. The 1-year patient survivals for groups 1, 2, and 3 were 100%, 87%, and 79%; respectively. 2-year survivals, 100%, 79%, and 61%, respectively. Survivals stratified by MELD showed no statistically remarkable differences in 1-year and 2-year patient survival (P = .08). In contrast, 1-year and 2-year patient survival rates for UNOS status 2A, 2B, and 3 were 73%-50%, 95%-91%, and 91%-91%, statistically significant difference (P = .002). Finally, to date preoperative MELD score showed no significant impact on 1- and 2-year posttransplant outcomes in adult-to-adult living donor liver transplantation recipients, but we await longer-term follow-up with greater numbers of patients.
机译:尚不清楚移植前的MELD(终末期肝病模型)评分是否可以预见移植后的结果。我们回顾性评估了1998年9月至2003年3月间接受活体供肝移植的80例成人患者(55例男性,25例女性)。另外五例暴发性肝炎患者被排除在外。计算UNOS修改后的MELD得分,将患者分为三组:第1组:MELD得分小于15(n = 13);第2组)MELD分数​​15至24(n = 36);以及第3组)MELD得分25分及更高(n = 26)。患者主要为男性(n = 52,69.3%),总平均年龄为43.9岁(范围17-62岁)。平均随访时间为15.7个月(范围:1-47;中位数= 14个月)。 MELD平均得分为22.7(范围:9-50;中位数= 21)。 1年和2年患者的总生存率分别为87%和78.7%。第1、2和3组的1年患者生存率为100%,87%和79%;分别。 2年生存率分别为100%,79%和61%。 MELD分层的生存率在1年和2年患者生存率上无统计学差异(P = .08)。相比之下,UNOS状态2A,2B和3的1年和2年患者生存率分别为73%-50%,95%-91%和91%-91%,差异有统计学意义(P = .002 )。最后,迄今为止,术前MELD评分对成年至成年活体供肝移植受者的1年和2年移植后结局均无显着影响,但我们仍在等待更多患者的长期随访。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号